-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Cirara
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Litifilimab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Tofersen Sodium
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s BIIB-061
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s SAGE-324
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Dapirolizumab pegol
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s DNL-151
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s BIIB-080
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Biogen Inc’s Aflibercept biosimilar
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Thematic Analysis
New![]()
Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes in Q3 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Pharma Sector
-
Product Insights
New![]()
Trigeminal Neuralgia (Tic Douloureux) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Trigeminal Neuralgia (Tic Douloureux) Clinical Trials Overview The Trigeminal Neuralgia (Tic Douloureux) clinical trial report consists of 129 trials. The report provides an overview of the Trigeminal Neuralgia (Tic Douloureux) clinical trials scenario. The report provides top-line data relating to the clinical trials on Trigeminal Neuralgia (Tic Douloureux). It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 &...
-
Company Profile
![]()
Vascular Biogenics Ltd – Company Profile
Vascular Biogenics Ltd (Vascular Biogenics), dba VBL Therapeutics, operates as a provider of biopharmaceutical products. The company discovers, develops and commercializes gene-therapy medicines for the treatment of cancer and inflammatory diseases. Its lead product candidate VB-111, a gene-based biologic agent is developed to treat recurrent glioblastoma, colon, ovarian, thyroid cancer and solid tumors. Its pipeline products include VB 201 and VB 703, oral small molecules being developed through lecinoxoids platform for treating cardiovascular diseases, liver and renal fibrosis. Vascular Biogenics...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Litifilimab in Systemic Lupus Erythematosus
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Litifilimab in Systemic Lupus Erythematosus Drug Details: BIIB-059 is under development for the treatment of...
-
Thematic Analysis
New![]()
Merger and Acquisition Deals of Top Themes by Industries in Q3 2023 – Thematic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 across all sectors including automotive, basic material, business and consumer services, consumer, energy, financial, healthcare, industrials, real estate, technology, media & telecoms, transportation, infrastructure, and logistics.
-
Product Insights
New![]()
Net Present Value Model: AbbVie Inc’s ABBVRGX-314
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Alaunos Therapeutics Inc’s Gene-Modified Cell Therapy to Target CD56 for Oncology
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
![]()
Chugai Pharma – Ukima Biogenic Drug Manufacturing Building – Tokyo
Equip yourself with the essential tools needed to make informed and profitable decisions with our Chugai Pharma - Ukima Biogenic Drug Manufacturing Building - Tokyo report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ASC-42 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ASC-42 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Drug Details: ASC-42 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BIIB-091 in Relapsing Remitting Multiple Sclerosis (RRMS)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BIIB-091 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug Details: BIIB-091 is under development for the treatment...
-
Product Insights
New![]()
Net Present Value Model: RegenxBio Inc’s RGX-111
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. RegenxBio Inc's RGX-111 Drug Details: RGX-111 is under development for the treatment of children and adult subjects with Mucopolysaccharidosis Type I (MPS I)....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.